Drug intelligence / Profile preview

Cicletanine + magnesium

Development stage
Phase 2
Lead developer
Gilead Sciences
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Cicletanine + magnesium is a combination of two agents with distinct pharmacological actions. Cicletanine is a furopyridine derivative and thiazide-like diuretic approved in France for the treatment of hypertension. It acts by inhibiting protein kinase C (PKC), reversing vasoconstriction through inhibition of PKC-mediated Na/K-ATPase phosphorylation, and may also stimulate vascular nitric oxide synthesis while inhibiting superoxide production. Magnesium (as magnesium citrate) is an osmotic laxative and mineral supplement that increases fluid in the colon via high osmolality and may stimulate peristalsis through cholecystokinin release. The combination could theoretically be used to address both hypertension (via cicletanine) and hypomagnesemia or constipation (via magnesium), but there are no widely recognized fixed-dose pharmaceutical products combining these two agents[1][2][4][5][6].

Other names
cycletanidecicletaninacicletanine hydrochloridemagnesium citrate
02

Targets

PKC (Protein kinase C family)

Beyond the preview

Go deeper on Cicletanine + magnesium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cicletanine + magnesium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call